[go: up one dir, main page]

WO2011024056A3 - Procédé perfectionné pour la préparation de bosentan - Google Patents

Procédé perfectionné pour la préparation de bosentan Download PDF

Info

Publication number
WO2011024056A3
WO2011024056A3 PCT/IB2010/002090 IB2010002090W WO2011024056A3 WO 2011024056 A3 WO2011024056 A3 WO 2011024056A3 IB 2010002090 W IB2010002090 W IB 2010002090W WO 2011024056 A3 WO2011024056 A3 WO 2011024056A3
Authority
WO
WIPO (PCT)
Prior art keywords
bosentan
preparation
improved process
deshydroxyethyl
sulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/002090
Other languages
English (en)
Other versions
WO2011024056A2 (fr
Inventor
Kumar Sinha Brajesh
Rajasekhara Raju Konduru
Shankar Reddy Budidet
Pandu Rangarao Vaddi
Islam Aminul
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2011024056A2 publication Critical patent/WO2011024056A2/fr
Publication of WO2011024056A3 publication Critical patent/WO2011024056A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur la purification de Bosentan brut par la formation de son sel de potassium cristallin, qui est encore converti en Bosentan (I) comprenant des impuretés bis-sulfonamide (VIII) et déhydroxyéthyle (IX) à hauteur inférieure à 0,2 % par analyse par HPLC.
PCT/IB2010/002090 2009-08-27 2010-08-27 Procédé perfectionné pour la préparation de bosentan Ceased WO2011024056A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2065CH2009 2009-08-27
IN2065/CHE/2009 2009-08-27
IN2132CH2010 2010-07-28
IN2132/CHE/2010 2010-07-28

Publications (2)

Publication Number Publication Date
WO2011024056A2 WO2011024056A2 (fr) 2011-03-03
WO2011024056A3 true WO2011024056A3 (fr) 2011-05-19

Family

ID=43033160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/002090 Ceased WO2011024056A2 (fr) 2009-08-27 2010-08-27 Procédé perfectionné pour la préparation de bosentan

Country Status (1)

Country Link
WO (1) WO2011024056A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130245259A1 (en) * 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
WO2013186706A1 (fr) * 2012-06-12 2013-12-19 Cadila Pharmaceuticals Ltd Procédé pour la préparation de bosentan
CN104193687B (zh) * 2014-07-01 2017-09-26 上海天慈国际药业有限公司 一种治疗肺动脉高压药物的制备方法
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
EP2072503A2 (fr) * 2007-12-18 2009-06-24 Dipharma Francis S.r.l. Procédé de préparation de bosentan
WO2009093127A2 (fr) * 2008-01-24 2009-07-30 Actavis Group Ptc Ehf Forme cristallisée stable et sensiblement pure de bosentan
WO2009095933A2 (fr) * 2008-01-10 2009-08-06 Msn Laboratories Limited Procédé perfectionné et nouveau pour la préparation de bosentan
WO2010032261A1 (fr) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Procédé pour la préparation de bosentan
WO2010103362A2 (fr) * 2009-03-11 2010-09-16 Sifavitor S.R.L. Procédé pour la préparation du bosentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CA2694242C (fr) 2007-06-29 2013-10-01 Generics [Uk] Limited Procede d'introduction d'une chaine laterale hydroxyethoxy dans le bosentan

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
EP2072503A2 (fr) * 2007-12-18 2009-06-24 Dipharma Francis S.r.l. Procédé de préparation de bosentan
WO2009095933A2 (fr) * 2008-01-10 2009-08-06 Msn Laboratories Limited Procédé perfectionné et nouveau pour la préparation de bosentan
WO2009093127A2 (fr) * 2008-01-24 2009-07-30 Actavis Group Ptc Ehf Forme cristallisée stable et sensiblement pure de bosentan
WO2010032261A1 (fr) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Procédé pour la préparation de bosentan
WO2010103362A2 (fr) * 2009-03-11 2010-09-16 Sifavitor S.R.L. Procédé pour la préparation du bosentan

Also Published As

Publication number Publication date
WO2011024056A2 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2009095933A3 (fr) Procédé perfectionné et nouveau pour la préparation de bosentan
WO2009004643A3 (fr) Procédé perfectionné pour la préparation de (s)-prégabaline et de ses intermédiaires
PH12012500634A1 (en) Processes for preparing of glucopyranosyl -substituted benzyl -benzene derivatives
AR078062A1 (es) Procedimiento de separacion de lignina a alta temperatura
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
AU2008258588A8 (en) Anti -inflammatory substituted cyclobutenedione compounds
MY161682A (en) Storage-stable 2-hydroxy-4- (methylthio) butyronitrile
WO2010147302A3 (fr) Nouveaux intermédiaires de voriconazole et procédé de préparation de voriconazole les utilisant
WO2011024192A3 (fr) Nouveaux polymorphes du raltegravir
WO2010064109A3 (fr) Procédé de préparation amélioré de montélukast sodique et ses intermédiaires
IN2012DN05209A (fr)
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
MY155284A (en) Process for the preparation of ajoene
WO2011024056A3 (fr) Procédé perfectionné pour la préparation de bosentan
UA106988C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та необхідні проміжні сполуки магнію
WO2009116081A3 (fr) Procédé amélioré de préparation daprépitant
WO2011058524A3 (fr) Formes cristallines du sel de bosentan et leurs procédés de préparation
WO2010107993A3 (fr) Procédé de préparation de (r)-n-benzyl-2-(benzyloxycarbonylamino)-3-méthoxypropionamide
WO2009060297A3 (fr) Procédé perfectionné pour la préparation de la palipéridone et de ses intermédiaires
WO2007143014A3 (fr) Méthodes de synthèse de dérivés d'acide glutamique et de leurs intermédiaires
WO2008096373A3 (fr) Procédé de synthèse de polymorphes de natéglinide extrêmement pure
GR1007722B (el) Μεθοδος για την παρασκευη της αριπιπραζολης
WO2010049947A3 (fr) Préparation de gemcitabine et de ses intermédiaires
WO2010079497A3 (fr) Nouveau polymorphe de sulfate d'atazanavir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10763229

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10763229

Country of ref document: EP

Kind code of ref document: A2